Synonym: Hydrocortisone 21-hemisuccinate monohydrate; 11β,17aα,21-Trihydroxy-4-pregnene-3,20-dione 21-hemisuccinate
CAS Number: 83784-20-7 (anhydrous)
Empirical Formula (Hill Notation): C25H34O8 · H2O
Molecular Weight: 480.55
Linear Formula: C25H34O8 · H2O
Product Type: Chemical
| API family |
hydrocortisone |
| application(s) |
pharmaceutical (small molecule) |
| format |
neat |
| grade |
pharmaceutical primary standard |
| InChI |
1S/C25H34O8.H2O/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30);1H2/t16-,17-,18-,22+,23-,24-,25-;/m0./s1 |
| InChI key |
AFLWPAGYTPJSEY-CODXZCKSSA-N |
| manufacturer/tradename |
USP |
| Analysis Note: |
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Application: |
- Hydrocortisone hemisuccinate in antioxidant research: This compound has been investigated for its antioxidant effects in models of induced oxidative stress, highlighting its potential in preventing conditions like cataracts, a common issue in ocular health. These studies underscore the corticosteroid′s capability to modulate oxidative damage, providing insights into broader anti-inflammatory and antioxidant therapy applications (Kundakci et al., 2023
  ).
- Hydrocortisone hemisuccinate for anti-inflammatory mechanisms: Research has explored the anti-inflammatory properties of hydrocortisone hemisuccinate in various experimental models. These studies contribute to understanding how corticosteroids can be used to manage inflammation, particularly in diseases where inflammation is a central component, further validating its use in clinical settings to control excessive immune responses (Davoudi et al., 2018 ).
- Hydrocortisone hemisuccinate in mucoadhesive applications: The development of mucoadhesive patches incorporating hydrocortisone hemisuccinate for buccal application has demonstrated potential for localized treatment strategies, offering an alternative route of administration that could enhance patient compliance and therapeutic outcomes, particularly in managing oral conditions (You et al., 2015 ).
|
| General description: |
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia . |
| Other Notes: |
Sales restrictions may apply. |
| Symbol |
 GHS07 |
| Signal word |
Warning |
| Hazard statements |
H315 - H319 |
| Precautionary statements |
P305 + P351 + P338 |
| Hazard Codes |
Xi |
| Risk Statements |
36/37/38 |
| Safety Statements |
26 |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
